NDAORALPOWDERPriority Review
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALCIBIND is an oral powder formulation of cellulose sodium phosphate, a non-absorbed ion-exchange resin used to reduce urinary calcium excretion. It binds intestinal calcium and reduces its absorption, helping prevent recurrent kidney stone formation in patients with hypercalciuria. The drug addresses a niche metabolic disorder with limited modern competition.
LOE Approaching
This legacy product faces imminent loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting brand team focused on maximizing value in the final exclusivity window.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CALCIBIND offers experience in specialty/niche market management and the strategic challenges of defending a legacy product facing LOE. Roles will emphasize cost management, market segmentation, and competitive positioning rather than growth initiatives, making this suitable for early-career professionals seeking exposure to mature product lifecycle dynamics or those seeking lower-pressure, stable environments.
Brand Manager
Worked on CALCIBIND at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.